RPG Life Sciences Ltd
RPG Life Sciences Ltd Share Price Today: Live Updates & Key Insights
Get insights on RPG Life Sciences Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
RPG Life Sciences Ltd Share Price Chart
RPG Life Sciences Ltd Fundamentals
Traded Volume: 8,029
Market Cap(Cr): 3,728
Avg Traded Price 2245.39
1 Year return 10.91%
Upper Circuit 2,263.9
Lower Circuit 2,212.3
P/E TTM 17.00
P/B Ratio 130.00
Traded Value(Cr) 180.97
EPS TTM 130.250
Book value 130.250
Dividend 1.00%
RPG Life Sciences Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights RPG Life Sciences Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the RPG Life Sciences Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -3.41%
1M -6.09%
3M -3.82%
1Y +10.91%
YTD +1.30%
RPG Life Sciences Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights RPG Life Sciences Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 5556.00
Day Before Yesterday 33863.00
1W Avg 25414.00
1M Avg 11533.24
3M Avg 13570.85
RPG Life Sciences Ltd Technical Details
RPG Life Sciences Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 2223
Support 2 2192
Support 3 2171
Pivot Point : 2243
Resistance 1 2275
Resistance 2 2295
Resistance 3 2326
RPG Life Sciences Ltd Corporate Actions
RPG Life Sciences Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on RPG Life Sciences Ltd’s capital allocation strategies.
All
Ex-Date 27-Jun-2025 Type D Description 20.00/share@250.00% Record Date 27-Jun-2025 Ratio 250.00
Ex-Date 27-Jun-2025 Type D Description 4.00/share@50.00% Record Date 27-Jun-2025 Ratio 50.00
Ex-Date 28-Jun-2024 Type D Description 16.00/share@200.00% Record Date 28-Jun-2024 Ratio 200.00
Ex-Date 21-Jul-2023 Type D Description 12.00/share@150.00% Record Date 21-Jul-2023 Ratio 150.00
Ex-Date 14-Jul-2022 Type D Description 9.60/share@120.00% Record Date 15-Jul-2022 Ratio 120.00
Ex-Date 13-Aug-2021 Type D Description 7.20/share@90.00% Record Date 17-Aug-2021 Ratio 90.00
Ex-Date 24-Mar-2020 Type D Description 4.00/share@50.00% Record Date 26-Mar-2020 Ratio 50.00
Ex-Date 22-Jul-2019 Type D Description 2.40/share@30.00% Record Date - Ratio 30.00
Ex-Date 19-Jul-2018 Type D Description 2.40/share@30.00% Record Date - Ratio 30.00
Ex-Date 13-Jul-2017 Type D Description 2.80/share@35.00% Record Date - Ratio 35.00
Ex-Date 22-Mar-2016 Type D Description 1.60/share@20.00% Record Date 24-Mar-2016 Ratio 20.00
Ex-Date 20-Jul-2015 Type D Description 0.80/share@10.00% Record Date - Ratio 10.00
Ex-Date 11-Sep-2014 Type D Description 0.80/share@10.00% Record Date - Ratio 10.00
Ex-Date 11-Sep-2014 Type D Description 1.20/share@15.00% Record Date - Ratio 15.00
Ex-Date 11-Jul-2013 Type D Description 1.20/share@15.00% Record Date - Ratio 15.00
Ex-Date 24-Jul-2012 Type D Description 0.80/share@10.00% Record Date - Ratio 10.00
Ex-Date 14-Jul-2011 Type D Description 1.60/share@20.00% Record Date - Ratio 20.00
Ex-Date 15-Jul-2010 Type D Description 1.44/share@18.00% Record Date - Ratio 18.00
Ex-Date 30-Jul-2009 Type D Description 1.20/share@15.00% Record Date - Ratio 15.00
Ex-Date 11-Aug-2008 Type D Description 1.20/share@15.00% Record Date - Ratio 15.00
Dividends
Announcement Date 27-Jun-2025 Ex Dividend Date 27-Jun-2025 Dividend(%) 250
Announcement Date 27-Jun-2025 Ex Dividend Date 27-Jun-2025 Dividend(%) 50
Announcement Date 28-Jun-2024 Ex Dividend Date 28-Jun-2024 Dividend(%) 200
Announcement Date 21-Jul-2023 Ex Dividend Date 21-Jul-2023 Dividend(%) 150
Announcement Date 14-Jul-2022 Ex Dividend Date 14-Jul-2022 Dividend(%) 120
Announcement Date 13-Aug-2021 Ex Dividend Date 13-Aug-2021 Dividend(%) 90
Announcement Date 24-Mar-2020 Ex Dividend Date 24-Mar-2020 Dividend(%) 50
Announcement Date 22-Jul-2019 Ex Dividend Date 22-Jul-2019 Dividend(%) 30
Announcement Date 19-Jul-2018 Ex Dividend Date 19-Jul-2018 Dividend(%) 30
Announcement Date 13-Jul-2017 Ex Dividend Date 13-Jul-2017 Dividend(%) 35
Announcement Date 22-Mar-2016 Ex Dividend Date 22-Mar-2016 Dividend(%) 20
Announcement Date 20-Jul-2015 Ex Dividend Date 20-Jul-2015 Dividend(%) 10
Announcement Date 11-Sep-2014 Ex Dividend Date 11-Sep-2014 Dividend(%) 10
Announcement Date 11-Sep-2014 Ex Dividend Date 11-Sep-2014 Dividend(%) 15
Announcement Date 11-Jul-2013 Ex Dividend Date 11-Jul-2013 Dividend(%) 15
Announcement Date 24-Jul-2012 Ex Dividend Date 24-Jul-2012 Dividend(%) 10
Announcement Date 14-Jul-2011 Ex Dividend Date 14-Jul-2011 Dividend(%) 20
Announcement Date 15-Jul-2010 Ex Dividend Date 15-Jul-2010 Dividend(%) 18
Announcement Date 30-Jul-2009 Ex Dividend Date 30-Jul-2009 Dividend(%) 15
Announcement Date 11-Aug-2008 Ex Dividend Date 11-Aug-2008 Dividend(%) 15
Bonus
No Bonus has been declared by RPGLIFE
Splits
No Split has been declared by RPGLIFE
Others
Rights No Rights has been declared by RPGLIFE
RPG Life Sciences Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares RPG Life Sciences Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate RPG Life Sciences Ltd's relative performance and valuation against major competitors.
Stock Name Aarti Drugs Ltd ₹442.10 (-1.05%) M. Cap (Cr) 40.64 1 Yr Return (%) -2.78% P/E (TTM) 20.27 PB Ratio 3.16
Stock Name Senores Pharmaceuticals Ltd ₹819.55 (-0.75%) M. Cap (Cr) 37.74 1 Yr Return (%) NaN% P/E (TTM) 43.32 PB Ratio 4.80
Stock Name Dishman Carbogen Amcis Ltd ₹237.95 (-3.33%) M. Cap (Cr) 37.31 1 Yr Return (%) +8.89% P/E (TTM) 27.35 PB Ratio 0.65
Stock Name RPG Life Sciences Ltd ₹2254.00 (+1.30%) M. Cap (Cr) 37.28 1 Yr Return (%) +10.91% P/E (TTM) 17.31 PB Ratio 9.83
Stock Name Gufic BioSciences Ltd ₹352.45 (+2.86%) M. Cap (Cr) 35.34 1 Yr Return (%) -13.10% P/E (TTM) 62.10 PB Ratio 6.16
Stock Name Unichem Laboratories Ltd ₹466.40 (-2.48%) M. Cap (Cr) 32.84 1 Yr Return (%) -45.80% P/E (TTM) 37.12 PB Ratio 1.34
Stock Name Hikal Ltd ₹224.98 (-1.46%) M. Cap (Cr) 27.74 1 Yr Return (%) -41.82% P/E (TTM) 274.66 PB Ratio 2.20
RPG Life Sciences Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by RPG Life Sciences Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 77.86 Mar 2024 94.36 Mar 2023 90.82 Mar 2022 64.75 Mar 2021 58.27
PARTICULARS Investing Activities Mar 2025 -41.80 Mar 2024 -79.15 Mar 2023 -105.81 Mar 2022 -34.66 Mar 2021 -7.96
PARTICULARS Financing Activities Mar 2025 -27.08 Mar 2024 -20.31 Mar 2023 -17.13 Mar 2022 -13.51 Mar 2021 -10.49
PARTICULARS Net Cash Flow Mar 2025 8.98 Mar 2024 -5.10 Mar 2023 -32.12 Mar 2022 16.58 Mar 2021 39.82
RPG Life Sciences Ltd Shareholding Pattern
This shows the ownership breakdown of RPG Life Sciences Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 72.95%
Public 19.23%
Other Institutions 3.5%
FII 1.11%
Mutual Funds 3.2%
About RPG Life Sciences Ltd
RPG Life Sciences Limited, formerly known as Searle India Limited, started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group. The Company is engaged in manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).RPG Life Sciences Limited was incorporated on March 29, 2007 with the name 'RPG Pharmaceuticals Limited' . During the year 2007-08, as per the Scheme of Arrangement, the Company acquired the Pharmaceuticals Business of Brabourne Enterprises Limited along with all assets and liabilities pertaining to that business with effect from April 2, 2007. On February 13, 2008, the name of the Company was changed to RPG Life Sciences Limited.During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, Qugyl-O & Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters. During the year 2009-10, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments.The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology.New products launched were Demator, Sizomax, Mela, Exinia and Mofetyl S during the year 2009-10. The Company strengthened its product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. It launched a new immunosuppressant product, Sirolimus in 2010.New divisions were launched in highly growing chronic segments namely Cardiology and Diabetic (IMPULSE), NeurologyPsychiatry (EMPATHY) and Oncology (Neo-life). A new division ESSENTIA was also launched to cater to the Hospital sales segment in 2010-11. New products launched were Seretane 2 DT, Rabee 20, Pedimec, Minilactone, Alfalog, Demator, Naprosyn Gel, Lamotrigine dispersible tablets. The Company sold its Biotech Unit located at Ankleshwar to M/s. Intas Pharmaceuticals Limited as a going concern in 2016-17. It acquired 7 brands from Sun Pharmaceuticals Limited, set up two new divisions viz. `Urolife' catering to the urology therapy and `Glodiance` division catering to the Cosmetic Derma therapy in 2016-17.In 2017-18, the Company launched brands Darbepoetin (Darba) and Rituximab (XMAB), in the post-transplant care space. Both the brands displayed robust performances in the first year of launch with Darba at third slot among competing Darbepoetin brands. Among the existing products, Immunotac and Arpimune range showed strong growth. In the Africa region, the Company expanded its business with first commercial supply in FY'18. It retained leadership position in Mauritius, through anti-diabetic range while in Egypt, immunosuppressant range remained the best alternative to the innovator brands in the post organ transplant care space.During 2019, the Company focused on launching new products and driving active promotion in the immunosuppressant range of products and strengthened the oncology portfolio basket by introducing two new monoclonal antibodies. It launched a new product, T-JAKi (JAK Inhibitor) in the immunosuppressant range of products in Rheumatology and Gastroenterology in FY21. As a part of Life Cycle Management strategy of legacy products, Romilast BL and Aldactone T new line extensions were launched. Azoran 75 mg new line extension was launched in 2021. Naprosyn+ and Aldactone-F was launched in FY 2022.In 2024, the Company launched a digital platform for comprehensive doctor engagement, `RPGserv,' which integrates physical and digital capabilities. The Company's portfolio has been strengthened by new launches in Cardiovascular, Diabetology, Nephrology, Rheumatology, Oncology and Urology segments and by entering clinical Dermatology, Orthopedic and Critical Care segments in FY24-25.
Chairman (Non-Executive)
H V Goenka
Registered office RPG House, 463 Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030
FAX :91-022-24981650
Background
Incorporation Year 2007
Face Value ₹8.00
Market Lot 1
FAQs on RPG Life Sciences Ltd
How to buy RPG Life Sciences Ltd shares on NSE?
To buy RPG Life Sciences Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the RPG Life Sciences Ltd share price today?
The RPG Life Sciences Ltd share price on NSE is ₹2254.00 today.
What is the market cap of RPG Life Sciences Ltd on NSE?
The company has a market capitalization of ₹3727.89.
What is the PE & PB ratio of RPG Life Sciences Ltd?
PE is 17 and PB is 130.
What is the 52 Week High and Low of RPG Life Sciences Ltd shares?
RPG Life Sciences Ltd stock price high: ₹2725 RPG Life Sciences Ltd stock price low: ₹1835.